Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The company said it has decided to price its version of Risdiplam product at Rs 15,900, and further added that it intends to ...

Parents of children with spinal muscular atrophy (SMA), a rare disease, welcomed the announcement by the Indian pharma ...

The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, ...

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch ...

The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify ...

Affordable generic version of SMA drug Risdiplam soon available in India, offering hope to patients and activists.

Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.

A two-judge bench of Delhi High Court on Wednesday refrained Natco Pharma from launching the generic version of Swiss drugmaker Roche Pharma's patented drug Risdiplam until the hearing on April 2.

The Delhi High Court on Monday refused to allow a lawsuit filed by Swiss pharmaceutical company Roche that sought to restrain Indian drug maker Natco Pharma from manufacturing Risdiplam ...

Natco Pharma started in Hyderabad with an investment of ₹3.3 million in 1981 and 20 employees working at a single unit. Today ...